APOTHEEK KESTEMONT
ActiveFrom the official registers: KBO 19 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
APOTHEEK KESTEMONT has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €800,523 and a net result of €231,908. Equity has been growing by about 14% per year since 2019. Its solvency ranks better than 59% of 12,757 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Official details
KBO- Status
- Active since 27-04-2006 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Establishment unit
- 2.153.489.773 1930 Zaventem, since 01-07-2006
- Financial year end
- 30 June
- Peppol
- Reachable since 09-07-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.2%
- Gross margin
- €634,544
- ▲ 16.6%
- Turnover
- ≈ €2.3m
- estimated
- Profit
- €231,908
- ▲ 375%
- Equity
- €800,523
- ▲ 14.0%
- Total assets
- €1.8m
- ▲ 23.6%
- Staff
- 5.7 FTE
- ▲ 23.9%
Score breakdownraises riskSector: Retail trade (NACE 47)lowers riskFounded in 2006Equity €800,523 (44.6% of total assets)Figures for financial year 2025 (filed on 21-11-2025)Show the evidence
Checked score
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 59% of them on solvency, 46% on liquidity, 79% on profitability and 66% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 65 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Key points
- Positive: Result rose in 2025from €48,856 to €231,908 ▲ 375% View
- Positive: Higher net result than 90% of companies in retail tradesector median €27,641 · 12,747 companies €231,908 View
- Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
- Positive: 7 profitable years in a rowprofit 2025: €231,908 7 years View
Comparable companies
These companies have the same main activity as APOTHEEK KESTEMONT: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.5m and €2m, founded between 2003 and 2008.
| Company | Total assets | Gross margin |
|---|---|---|
| APOTHEEK KESTEMONT Zaventem | €1.8m | €0.6m |
| OPNIPHAR Buggenhout | €1.9m | €0.6m |
| PHARMACIE CHARUE Fleurus | €1.8m | €0.7m |
| DE LUCHTHAVEN APOTHEEK Zaventem | €1.5m | €0.8m |
| Apotheek Heungens - Ghyzelings Merelbeke-Melle | €1.5m | €0.6m |
| Westlaanapotheek Roeselare | €2.0m | €0.7m |
| PHARMACIE RONLEZ Ath | €2.0m | €0.5m |
Documents
Annual accounts at the NBB
- Annual accounts 2025filed on 19-11-2025
- Annual accounts 2024filed on 26-11-2024
- Annual accounts 2023filed on 05-12-2023
- Annual accounts 2022filed on 07-12-2022
Acts in the Belgian Official Gazette
- Legal-form change · Name · Resignations & appointmentsact of 15-05-2024
Articles and registers
- Coordinated articles of associationnotaries' database
- Entry in the KBO registerKBO Public Search
Key facts about APOTHEEK KESTEMONT
- What is the company number of APOTHEEK KESTEMONT?
- The company number of APOTHEEK KESTEMONT is 0880.968.549. The VAT number is the same number with BE in front: BE 0880.968.549.
- Where is APOTHEEK KESTEMONT based?
- The registered office is at Hoogstraat 23, 1930 Zaventem.Company details
- What does APOTHEEK KESTEMONT do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of APOTHEEK KESTEMONT?
- The legal form of APOTHEEK KESTEMONT is Private limited company (BV).
- When was APOTHEEK KESTEMONT founded?
- APOTHEEK KESTEMONT was founded on 27-04-2006.
- Is APOTHEEK KESTEMONT still active?
- Yes, APOTHEEK KESTEMONT is an active enterprise in the KBO register.
- How many employees does APOTHEEK KESTEMONT have?
- APOTHEEK KESTEMONT had an average of 5.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of APOTHEEK KESTEMONT?
- The turnover in financial year 2025 is ≈ €2.3m. This figure is estimated from the gross margin of €634,544 and 47 comparable companies (NACE 477). It probably lies between €1.8m and €3.8m.
- Is APOTHEEK KESTEMONT profitable?
- In financial year 2025, APOTHEEK KESTEMONT made a profit of €231,908.
- Where can I find the annual accounts of APOTHEEK KESTEMONT?
- APOTHEEK KESTEMONT filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts 2025 (PDF)
- When are the next annual accounts of APOTHEEK KESTEMONT due?
- APOTHEEK KESTEMONT must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.